Psilocybin Prevents Reinstatement of Alcohol Seeking by Disrupting the Reconsolidation of Alcohol-related Memories

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2023 Jun 2

PMID 37266686

Authors

F Benvenuti

D Colombo

L Soverchia

N Cannella

E Domi

R Ciccocioppo

Affiliations

Soon will be listed here.

Abstract

Background: For most psychiatric conditions, including alcohol use disorder (AUD), FDA-approved pharmacological treatments are limited and their efficacy is restricted to only certain subgroups of patients. Scientific interest in the potential of psychedelic drugs has dramatically increased because of clinical preliminary evidence of efficacy in treating various psychiatric disorders. One of the most promising compounds belonging to this class of molecules is psilocybin. Here, to elucidate the therapeutic potential and treatment modalities of this drug, we investigated the effect of psilocybin on alcohol drinking and seeking in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats, a well validated animal model of AUD characterized by excessive drinking and seeking.

Methods: Using male and female msP rats, we tested the effect of psilocybin on home cage voluntary alcohol consumption. We also tested the effect of the drug on the alcohol deprivation effect (ADE) model of relapse and on cue-induced reinstatement of alcohol seeking after a period of abstinence. Finally, we evaluated if psilocybin may disrupt the reconsolidation process of alcohol-related memory.

Results: Psilocybin did not reduce alcohol consumption, nor it prevented increased alcohol drinking after a period of forced abstinence and cue-induced reinstatement of alcohol-seeking. Noteworthy, in a memory retrieval-reconsolidation paradigm, psilocybin markedly attenuated resumption of alcohol seeking.

Conclusions: Altogether these data suggest that, despite psilocybin does not affect alcohol drinking and relapse, it may be highly effective if used to block the reconsolidation process of alcohol-related memories. This opens to the possibility of using this psychedelic drug in clinical settings in which AUD patients undergo procedures to recall the memory of alcohol and are then treated with psilocybin during the memory reconsolidation phase.

Citing Articles

Distinct 5-HT receptor subtypes regulate claustrum excitability by serotonin and the psychedelic, DOI.

Anderson T, Keady J, Songrady J, Tavakoli N, Asadipooya A, Neeley R Prog Neurobiol. 2024; 240:102660.

PMID: 39218140 PMC: 11444019. DOI: 10.1016/j.pneurobio.2024.102660.

Interfering with reconsolidation by rimonabant results in blockade of heroin-associated memory.

Lin J, Peng Y, Zhang J, Cheng J, Chen Q, Wang B Front Pharmacol. 2024; 15:1361838.

PMID: 38576487 PMC: 10991728. DOI: 10.3389/fphar.2024.1361838.

Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies.

Hilal F, Jeanblanc J, Deschamps C, Naassila M, Pierrefiche O, Ben Hamida S J Neural Transm (Vienna). 2024; 131(5):525-561.

PMID: 38554193 DOI: 10.1007/s00702-024-02757-3.

References

Koob G, Roberts A, Kieffer B, Heyser C, Katner S, Ciccocioppo R . Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology. Recent Dev Alcohol. 2003; 16:263-81. DOI: 10.1007/0-306-47939-7_19. View

Muthukumaraswamy S, Carhart-Harris R, Moran R, Brookes M, Williams T, Errtizoe D . Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013; 33(38):15171-83. PMC: 6618409. DOI: 10.1523/JNEUROSCI.2063-13.2013. View

Cameron L, Benson C, Dunlap L, Olson D . Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. ACS Chem Neurosci. 2018; 9(7):1582-1590. PMC: 7196340. DOI: 10.1021/acschemneuro.8b00134. View

Doss M, Povazan M, Rosenberg M, Sepeda N, Davis A, Finan P . Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021; 11(1):574. PMC: 8575795. DOI: 10.1038/s41398-021-01706-y. View

Daws R, Timmermann C, Giribaldi B, Sexton J, Wall M, Erritzoe D . Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022; 28(4):844-851. DOI: 10.1038/s41591-022-01744-z. View

Litten R, Falk D, Ryan M, Fertig J, Leggio L . Advances in Pharmacotherapy Development: Human Clinical Studies. Handb Exp Pharmacol. 2018; 248:579-613. DOI: 10.1007/164_2017_79. View

Xue Y, Luo Y, Wu P, Shi H, Xue L, Chen C . A memory retrieval-extinction procedure to prevent drug craving and relapse. Science. 2012; 336(6078):241-5. PMC: 3695463. DOI: 10.1126/science.1215070. View

de Veen B, Schellekens A, Verheij M, Homberg J . Psilocybin for treating substance use disorders?. Expert Rev Neurother. 2016; 17(2):203-212. DOI: 10.1080/14737175.2016.1220834. View

Lee J, Di Ciano P, Thomas K, Everitt B . Disrupting reconsolidation of drug memories reduces cocaine-seeking behavior. Neuron. 2005; 47(6):795-801. DOI: 10.1016/j.neuron.2005.08.007. View

10.

Johnson M, Richards W, Griffiths R . Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008; 22(6):603-20. PMC: 3056407. DOI: 10.1177/0269881108093587. View

11.

Carter O, Burr D, Pettigrew J, Wallis G, Hasler F, Vollenweider F . Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005; 17(10):1497-508. DOI: 10.1162/089892905774597191. View

12.

Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P . Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018; 23(11):3170-3182. PMC: 6082376. DOI: 10.1016/j.celrep.2018.05.022. View

13.

Miller C, Marshall J . Molecular substrates for retrieval and reconsolidation of cocaine-associated contextual memory. Neuron. 2005; 47(6):873-84. DOI: 10.1016/j.neuron.2005.08.006. View

14.

Rambousek L, Palenicek T, Vales K, Stuchlik A . The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat. Front Behav Neurosci. 2014; 8:180. PMC: 4032947. DOI: 10.3389/fnbeh.2014.00180. View

15.

Vengeliene V, Bilbao A, Spanagel R . The alcohol deprivation effect model for studying relapse behavior: a comparison between rats and mice. Alcohol. 2014; 48(3):313-20. DOI: 10.1016/j.alcohol.2014.03.002. View

16.

Robinson M, Franklin K . Effects of anisomycin on consolidation and reconsolidation of a morphine-conditioned place preference. Behav Brain Res. 2007; 178(1):146-53. DOI: 10.1016/j.bbr.2006.12.013. View

17.

Meinhardt M, Pfarr S, Fouquet G, Rohleder C, Meinhardt M, Barroso-Flores J . Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. Sci Adv. 2021; 7(47):eabh2399. PMC: 8598005. DOI: 10.1126/sciadv.abh2399. View

18.

Schneider M . Adolescence as a vulnerable period to alter rodent behavior. Cell Tissue Res. 2013; 354(1):99-106. DOI: 10.1007/s00441-013-1581-2. View

19.

Vengeliene V, Heidbreder C, Spanagel R . The effects of lamotrigine on alcohol seeking and relapse. Neuropharmacology. 2007; 53(8):951-7. DOI: 10.1016/j.neuropharm.2007.09.006. View

20.

Johnson M, Garcia-Romeu A, Cosimano M, Griffiths R . Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014; 28(11):983-92. PMC: 4286320. DOI: 10.1177/0269881114548296. View